Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study.

Julio Peguero,Davendra P S Sohal,Bert H O'Neil,Howard Safran,Karen Kelly,Juneko E Grilley-Olson,Vivek Subbiah,Lincoln Nadauld,Das Purkayastha,Erica Stealey, Alejandro D Ricart,Barinder P Kang,Joseph Paul Eder

JCO precision oncology（2019）

Cited 7|Views11

No score

Abstract

No new or unexpected safety signals were observed in this heavily pretreated patient population. Although responses were seen in tumors with - amplifications, the primary end point was not met, suggesting additional evaluation of ribociclib, possibly as combination therapy, is needed.

Translated text

Key words

ribociclib,cyclin,tumors,site-agnostic,open-label,single-arm

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined